Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Thursday, January 14, 2021 9:27:34 PM
Yes. After I burial results were reviewed, fast track was granted. Then the choice became whether to modify the trial into a Phase 3, which they did, but the FDA wanted to see a much larger number of subjects in spite of fast track.
Another option would have been to modify the phase 2 under new fast track protocol, but the phase 2 was either finishing or finished. Either way, fast track meant delaying the continuation to revise the protocol or apply for an advanced phase.
Fast track only means increased review and increased access to guidance and meetings. It reduces the time for review and approval, it doesn’t alter the trial parameters once a protocol is approved.
Under the current emergency, there is still no effective treatment that is affordable, that won’t bankrupt the average patient. The treatment course the President took would have cost anyone else $50k to $100k. So, there is a huge need for cheap until there is vaccine-based herd immunity. Fast track means more now, but that doesn’t mean the protocol needed to include the parameters of fast track.
If you still are confused, maybe someone else can better explain why waiting for fast track prior to submitting the final proposal and protocol was the smart thing to do to save time.
* Never borrow to invest.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM